Inactive Instrument

Weifa ASA

Equities

WEIFA

NO0010308240

Pharmaceuticals

Clavis Pharma ASA Appoints Synne Syrrist as Director

October 08, 2013 at 10:02 am EDT

Clavis Pharma ASA appointed Synne Syrrist as director of the company in the Extraordinary General Meeting held on 8 October 2013. Synne was previously deputy director.

Latest news about Weifa ASA

Weifa ASA Announces Board Appointments	17-10-17	CI
Karo Pharma AB (OM:KARO) completed the acquisition of Weifa ASA (OB:WEIFA) from Holta Life Sciences AS, Watrium AS and others.	17-10-05	CI
An unknown buyer acquired 9.1% stake in Weifa ASA (OB:WEIFA) from MVN Event Driven Master Fund Limited fund managed by MVN Asset Management Limited and MVN Asset Management Limited.	17-09-25	CI
Weifa ASA(OB:WEIFA) dropped from S&P Global BMI Index	17-09-18	CI
Karo Pharma AB (OM:KARO) entered into a transaction agreement to make an offer to acquire Weifa ASA (OB:WEIFA) from Holta Life Sciences AS, Watrium AS and others for NOK 1.3 billion.	17-08-23	CI
Weifa ASA Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017; Provides Earnings Guidance for the Year 2017	17-07-13	CI
Weifa ASA Announces Dividend, Payable on June 8, 2017	17-05-30	CI
Weifa ASA Announces Audited Consolidated and Parent Earnings Results for the Year Ended December 31, 2016	17-04-28	CI
The mutual funds managed by Nordea Funds Oy acquired an additional 0.54% stake in Weifa ASA (OB: WEIFA).	17-03-19	CI
Weifa ASA Proposes Dividend for the Fourth Quarter of 2016, Payable on June 8, 2017	17-02-16	CI
Weifa ASA Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016	17-02-16	CI
Weifa Announces New License Agreement with AFT Pharmaceuticals for Nordic Rights to Groundbreaking Product Line Within Pain Management	17-01-12	CI
Weifa ASA Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016; Provides Earnings Guidance for 2016	16-10-25	CI
Weifa ASA to Launch Lbux(R) 200 mg Soft Capsules to Strengthen its Pain Relief Portfolio	16-10-11	CI
Weifa ASA Launches Solvivo(R) Lozenges	16-09-14	CI
Weifa ASA Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016; Provides Earnings Guidance for Full Year of 2016	16-08-25	CI
Weifa ASA Announces the Launch of Zonat Tablets	16-08-10	CI
Weifa ASA (OB:WEIFA) announces an Equity Buyback for 20,000 shares, for NOK 0.02 million.	16-07-06	CI
Tranche Update on Weifa ASA (OB:WEIFA)'s Equity Buyback Plan announced on July 6, 2016.	16-07-06	CI
Weifa ASA authorizes a Buyback Plan.	16-07-05	CI
Weifa ASA's Equity Buyback announced on July 6,2016 has closed with 20,000 shares for NOK 0.02 million.	16-07-05	CI
Weifa ASA Signs Distribution Agreement with Fysioline Group	16-06-06	CI
Weifa ASA Declares Dividend, Payable on June 10, 2016	16-06-01	CI
Weifa ASA Proposes Dividend for First Quarter of 2016; Reports Earnings Results for the First Quarter of 2016; Announces Future Product Launches; Provides Earnings Guidance for the Year 2016	16-04-26	CI
Weifa ASA Secures New Loan Agreement with DNB	16-03-21	CI

Chart Weifa ASA

Duration

Period

More charts

Company Profile

Sector

Pharmaceuticals

More about the company

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.40%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.12%	14B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.06B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.8B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B

Generic Pharmaceuticals